Crinetics Pharmaceuticals (CRNX) Interest Expenses (2017)

Crinetics Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $121.6 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 5977.95% year-over-year to $121.6 million; the TTM figure through Mar 2026 stood at $121.6 million (up 8197.54% YoY), while the FY2025 annual figure was $392.0 million, up 16.11% from the prior year.
• Interest Expenses for Q1 2026 stood at $121.6 million, up from $1.7 million in the prior quarter.
• The five-year high for Interest Expenses was $356.6 million in Q3 2024, with the low at -$1.6 million in Q4 2024.
• The 5-year median for Interest Expenses is $27.8 million (2022), against an average of $98.3 million.
• The sharpest annual moves came in 2024 and 2026: Interest Expenses slumped 316.62% in 2024, then soared 5977.95% in 2026.
• Crinetics Pharmaceuticals' Interest Expenses stood at $300000.0 in 2022, then surged by 138.67% to $716000.0 in 2023, then plunged by 316.62% to -$1.6 million in 2024, then jumped by 207.16% to $1.7 million in 2025, then jumped by 7214.02% to $121.6 million in 2026.
• Business Quant data shows CRNX's Interest Expenses at $121.6 million in Q1 2026, $1.7 million in Q4 2025, and $201.9 million in Q3 2025.